Overview

STEMdiff™ Definitive Endoderm Kit (TeSR™-E8™ Optimized) is a complete, serum- and animal component-free medium and supplement kit that supports highly efficient differentiation of human ES cells and iPS cells that have been maintained in TeSR™-E8™ to definitive endoderm. Cells differentiated using the STEMdiff™ Definitive Endoderm Kit (TeSR™-E8™ Optimized) express high levels of endoderm markers, including CD184 (CXCR4) and SOX17. When used in combination with Vitronectin XF™, the STEMdiff™ Definitive Endoderm Kit (TeSR™-E8™ Optimized) provides a completely xeno-free workflow for the generation of multipotent definitive endoderm.

Optimized for differentiation of cells maintained in TeSR™-E8™ . For differentiation of cells maintained in mTeSR™1, please see the STEMdiff™ Definitive Endoderm Kit.

Subtype
Specialized Media
 

Cell Type
Airway Cells, Endoderm, PSC-Derived, Hepatic Cells, Intestinal Cells, Pancreatic Cells, Pluripotent Stem Cells
 

Species
Human
 

Application
Cell Culture, Differentiation
 

Brand
STEMdiff
 

Area of Interest
Cancer, Epithelial Cell Biology, Stem Cell Biology
 

Formulation Category
Animal Component-Free, Serum-Free

Product Advantages

- Defined, serum- and animal component-free medium for the differentiation of human ES and iPS cells to definitive endoderm in a complete, ready-to-use format

- Efficient and reproducible differentiation of multiple ES cell and iPS cell lines

- Generates definitive endoderm cells capable of further differentiation to pancreatic, hepatic, intestinal and pulmonary cell lineages

- Optimized for use with cells maintained in TeSR™-E8™ cell culture medium

What's Included

- STEMdiff™ Endoderm Basal Medium, 100 mL

- STEMdiff™ Definitive Endoderm Supplement MR (100X), 0.35 mL

- STEMdiff™ Definitive Endoderm Supplement CJ (100X), 1.1 mL

- STEMdiff™ Definitive Endoderm TeSR™-E8™ Supplement, 7 mL

Catalog #: 05115

Please email us at cs@medikonia.com for any enquiry. To place an order, please include the catalog number(s) of the product(s) in the email.